Published • loading... • Updated
Predicting the Progression Risk of Metabolic Syndrome-Related Fatty Liver Disease Through Blood Sampling: Focusing on C7! Shinshu University's Study on MASLD Progression Risk Based on Complement C7 in the Blood.
Summary by Dtimes
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
A research group from the Department of Internal Medicine II at Shinshu University School of Medicine has reported that blood complement C7 levels are associated with the progression of liver fibrosis and the risk of future liver-related events in patients with metabolic syndrome-induced fatty liver disease (MASLD). Further verification is needed before this can be used in clinical practice.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
